Methodologies for vaccine safety surveillance. Nick Andrews, Statistics Unit Public Health England October 2015
|
|
- Shona Francine Harper
- 5 years ago
- Views:
Transcription
1 Methodologies for vaccine safety surveillance Nick Andrews, Statistics Unit Public Health England October 2015
2 Some dramas of the past 20 years which do you think turned out to be real adverse reactions? Reduced Immunity / allergy Hep B vaccine MMR Type 1 Diabetes Chronic Fatigue Autism Aseptic Meningitis HPV vaccine Intussusception Convulsions Neurological problems Guillane Barre Syndrome Flu vaccine Rotavirus Vaccine Asthma Exacerbation Mercury in vaccines H1N1 Pandemic Vaccine Narcolepsy
3
4
5 Talk Overview The components of vaccine safety surveillance Epidemiological methods Example and comparisons Conclusions
6 Plausibility, other data/methods, experts, other risks, interval from vaccine,. Vaccine Safety Assessment Components Vaccine Trials reactogenicity Licensure and use Individual causality assessment Pharmacovigilance (passive/active): hypothesis generation, RAPID Epidemiological studies (hypothesis testing) Signal Strengthening/ assessment Priority?
7 Passive Surveillance systems Often part of Pharmacovigilance by regulatory authorities Many countries have a system in place (UK Yellow Card) Reports from health professionals / public are monitored. e.g. by comparing rates to historical rates or other vaccines (proportional reporting ratios). Some countries (e.g. US VAERS system) have stimulated passive reporting forms sent to all physicians for return
8 Active Surveillance example! Vaccine safety data link. Using data from US Health Maintenance Organisations! Rapid Cycle analysis e.g.comparing observed convulsions 0-1 days post trivalent influenza vaccine to expected numbers each week based on histyorcial data. Study by TSE et al, Vaccine Could look at many different outcomes this way
9 Signal strengthening Signals may come from many sources recent example HPV and Guillane Barre Syndome from a French cohort study What can be done to rapidly assess a signal? Go through the usual causality assessment steps but likely lots of missing information. WHO has guidelines. Look at pharmacovigilance data (if that was not the source of the signal). Ecological studies look in hospital / GP databases at disease rates over time. Observed v Expected studies within databases that contain vaccination data where reporting bias is less likely. Ideally already be looking at possible events of interest in rapid cycle analysis.
10 Rapid Ecological study of Guillane Barre Syndome and HPV vaccine (done in a few days) Hospitalisations for GBS by age and period and whether vaccine scheduled that year (red) No increased risk seen
11 Epidemiological studies for Investigating adverse events Design issues Exact question/vaccine/population, case definition, timing relative to vaccination, confounders, how rare. Data sources For cases, vaccination, confounders (?linkage) Methods Cohort, case-control, case-coverage, case-only (self controlled case series) BEST ONE OFTEN DEPENDS ON DATA SOURCES AND DESIGN ISSUES
12 Comparing designs: Example1: Rotavirus and Intussusception October 1998: an anti-rotavirus vaccine is launched in the USA for use in infants (3 doses). May 1999: the vaccination programme is suspended following 9 reports of intussusception temporally associated with vaccination. An epidemiological investigation is launched.
13 Main design was a case-control study 382 cases and 1657 controls, matched/controlled for sex, age, hospital of birth, proxies for socio-economic position. But control selection difficult could there be residual confounding. So also considered just looking at all the cases (432 could be used) for the timing of any vaccines using self controlled case series.
14 Self Controlled Cases-Series (SCCS) Just obtain data on cases Design For each individual each day and event in the study period will fall inside or outside the risk period. vaccination Event Jan 01 Dec 01 risk period Relative incidence calculated in a similar way to a cohort study but analysis is conditional Poisson regression i.e. data are not aggregated across individuals so each individual has a set of exposure periods and events
15 Interval between vaccination and intussusception in 74 vaccinated cases Murphy et al (2001) NEJM
16 Results for the first dose Risk period (days) Case-control SCCS (12.6, 110) 58.9 (31.7, 110) (2.4, 27.6) 9.4 (3.9, 22.3) (0.2, 5.4) 2.3 (0.5, 10.2) Conclusion: Possibly some residual confounding in the case-control design Almost all studies of intussusception since this have used the SCCS design you only need the cases. SCCS implicitly controls for non-time varying confounders.
17 Example2: MMR and Autism studies Study Sample size RI / OR SCCS (UK 1999) Cohort (Denmark -2002) Case-control (UK 2004) 95% CI 357 cases 0.88 (0.40, 1.95) children 316 cases 1294 cases 4469 controls 0.92 (0.68, 1.24) 0.86 (0.68, 1.09) In this case SCCS worked well, although it is more suited to clearer acute onsets.
18 Example3: Asthma exacerbation and flu vaccine Kramarz et al, Arch. Fam. Med. 2000, 9: Cohort and case series studies in asthmatic children aged 1 6 years in 1995/6. Risk period: 2 weeks after flu vaccine. Method Sample size RI 95% CI Cohort, unadjusted (2.55, 4.15) Cohort, adjusted (1.08, 1.77) Case series 2075 cases 0.98 (0.76, 1.27) The cohort results are subject to indication bias. The case series results are unaffected by this bias.
19 Example4: GBS, flu vaccine and flulike illness Stowe et al, Am. J. Epidemiol. 2008, 169: Observation period: all time within GPRD in Two types of exposures: flu vaccination and flu-like illness. Risk periods: 0-30, 31-60, days after vaccine/onset Pre-exposure risk period: 2 weeks Age groups: 12 periods over years Seasonal groups: calendar month Repeat episodes: included if > 6 months separation
20 Results 775 distinct episodes in 690 individuals Flu vaccine: 0 30 days: RI = 0.58 (0.18, 1.86) 0 90 days: RI = 0.76 (0.41, 1.40) Influenza-like illness: 0 30 days: RI = (9.37, 29.54) 0 90 days: RI = 7.35 (4.36, 12.38)
21 Interval between influenza-like illness and GBS From: Stowe et al, Am. J. Epidemiol. 2008, 169:
22 Example 5: Pandemrix vaccine and Narcolepsy Miller et al, BMJ 2013 Pandemrix (AS03 adjuvanted H1N1 vaccine) used widely in Europe Signal of possible narcolepsy association from Sweden / Denmark Epi studies to date have been cohort, case-control, casecoverage and SCCS.
23 Choice of study design (UK) SAMPLE SIZE calculations suggested we needed to cover a large proportion of cases in England. Cohort > No national database for vaccinations. Case-control> Possible but control selection and cost/ ethical permissions issues with getting controls. SCCS> Yes although potential problems with defining risk interval and having enough follow up time for power. Case-coverage>Yes since we have good coverage data in GP databases such as RCGP.
24 Study Design Age: 4 to 18 year olds at diagnosis Period: Onset from Jan 2008 and diagnosed by the time of the visit. Case finding: 23 sleep centres Validation: of cases using ICSD-2 criteria by 3 experts using notes obtained at centre visits. Key index date: Onset of excessive daytime sleepiness (EDS) / cataplexy as reported in case notes or by a GP Vaccination history: obtained from a letter to the GP. Details of being in a risk group targeted for vaccination were also obtained from GPs. Case - coverage compares odds of vaccination in cases to the age and risk group matched population
25 Non risk group RCGP Coverage data for casecoverage design Risk group
26 Cases by EDS date and vaccination status
27 Results vaccine association OR = 14.4, 95% CI( ) for vaccinated at any time prior to onset. Attributable risk: 1.9 per 100,000 doses. Other designs (results here based on first symptoms for children and Pandemrix): France case matched to hospital controls OR = 21.5 ( ) Finland retrospective cohort design RI ~ 25 (8-80) UK SCCS did not work well because no clear risk window, lack of control unexposed time and correlation of period effects and vaccine effects as all vaccine given over a few months.
28 Design Pros and Cons Case Control Pros can get detailed information on cases and controls Cons control selection may lead to bias Cohort Pros direct estimates of risks, high power Cons may be limited data on possible confounders, may be difficult to construct the cohort (linkage). Self Controlled Case Series Pros just need cases so cheaper. Automatic adjustment for nontime varying confounders Cons usually need a risk window to be specified, sometimes colinearity of vaccine and age/time effects. Case-Coverage Pros simple to use with routine data without linkage. Cons usually limited matching to confounders
29 Conclusions Post licensure vaccine safety surveillance is an important component of a vaccine programme It is important to be able to perform controlled epidemiological studies rapidly and to be aware of potentially confounding / bias Record linkage and the SCCS method has proved an excellent tool for such studies. Cohort and other designs such as case-coverage are also required for some events where SCCS is not ideal. NEW QUESTIONS KEEP ARISING!
30 Acknowledgements! PHE: Liz Miller, Julia Stowe, Pauline Kaye! Royal Free: Brent Taylor! Open University: Paddy Farrington, Heather Whitaker
31 EXTRA SLIDES: Useful resources WHO Global Vaccine Safety Initiative: vaccine_safety/en/ FDA: Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment index.htm ADVANCE consortium looking at vaccine benefit risk SCCS Website: Created by Heather Whitaker to be updated in the next year or so Tutorial paper: Whitaker et al., Statist. Med. 2006, 25: Useful overview of case-only methods: Farrington, Vaccine 2005, Control without separate controls:
32 Comparing designs
Population-based post-licensure safety surveillance
Population-based post-licensure safety surveillance Nick Andrews, Public Health England With thanks to Paddy Farrington, Open University for contributing some SCCS slides ADVAC May 27 th 2016 Aims of the
More informationVACCINE ACTIVE SURVEILLANCE I
VACCINE ACTIVE SURVEILLANCE I Caitlin N Dodd, MS Biostatistician, Global Child Health Cincinnati Children s Hospital Medical Center CONTENTS M1 Compare epidemiological study methods Discuss the benefits
More informationInfluenza vaccine effectiveness assessment in the UK. Nick Andrews, Statistics Unit, Health Protection Agency
Influenza vaccine effectiveness assessment in the UK Nick Andrews, Statistics Unit, Health Protection Agency 1 Outline Introduction The UK swabbing schemes Assessment by the test negative case control
More informationGlobal Advisory Committee on Vaccine Safety (GACVS) Report from the June 2017 meeting
Global Advisory Committee on Vaccine Safety (GACVS) Report from the June 2017 meeting Topics discussed in June Safety monitoring of the RTS,S vaccine pilot implementation programme Safety update of BCG
More informationI n 1995, Plesner reported 24 cases of temporary gait
292 ORIGINAL ARTICLE No evidence of an association between MMR vaccine and gait disturbance E Miller, N Andrews, A Grant, J Stowe, B Taylor... See end of article for authors affiliations... Correspondence
More informationMarc Baguelin 1,2. 1 Public Health England 2 London School of Hygiene & Tropical Medicine
The cost-effectiveness of extending the seasonal influenza immunisation programme to school-aged children: the exemplar of the decision in the United Kingdom Marc Baguelin 1,2 1 Public Health England 2
More informationInfluenza Vaccine Safety Monitoring Update
Influenza Vaccine Safety Monitoring Update Advisory Committee on Immunization Practices October 28, 2010 Tom Shimabukuro, MD, MPH, MBA Immunization Safety Office Division of Healthcare Quality Promotion,
More informationAssessing the Safety of Vaccines at the FDA: Pre- and Post-Licensure Evaluation
Assessing the Safety of Vaccines at the FDA: Pre- and Post-Licensure Evaluation Karen Farizo, M.D. Office of Vaccines Research and Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationPneumococcal polysaccharide vaccine uptake in England, , prior to the introduction of a vaccination programme for older adults
Journal of Public Health Advance Access published July 7, 2006 Journal of Public Health pp. 1 of 6 doi:10.1093/pubmed/fdl017 Pneumococcal polysaccharide vaccine uptake in England, 1989 2003, prior to the
More informationAssessing Vaccine Safety Post Licensure. Neal A. Halsey Johns Hopkins University
Assessing Vaccine Safety Post Licensure Neal A. Halsey Johns Hopkins University Inactivated Respiratory Syncytial Virus Vaccine: 1960 s Formalin inactivated Administered to infants Minimal reactions Induced
More informationExperience with maternal pertussis and PCV13 immunisation in England
Experience with maternal pertussis and PCV13 immunisation in England Immunisation, Hepatitis & Blood Safety department Public Health England 5th RIVM Vaccine Preventable Diseases Research day 18 th November
More informationInvestigation of the association between narcolepsy and vaccination with Pandemrix
Investigation of the association between narcolepsy and vaccination with Pandemrix Darina O Flanagan Director HPSC HSE AS Barret, S Cotter, C Bonner, C Crowe, B Lynch, B Sweeney, M Foley, H Johnson, B
More informationSelf-controlled case-series method
Self-controlled case-series method Presented by StellaMay Gwini Biostatistical Consultancy Platform, DEPM Objectives To describe the self-controlled case-series method Highlight possible uses of SCCS within
More informationUsing the Self-Controlled Risk Interval (SCRI) Method to Study Vaccine Safety
info@sentinelsystem.org 1 Using the Self-Controlled Risk Interval (SCRI) Method to Study Vaccine Safety W. Katherine Yih, PhD, MPH Sentinel/PRISM Epidemiology of Vaccine Safety ICPE pre-conference course,
More informationRegulatory Challenges for Influenza Vaccines 1
Regulatory Challenges for Influenza Vaccines 1 Regulatory Challenges for Influenza Vaccines Leonoor Wijnans - Influenza Summer School Siena, 19 July 2012 Regulatory challenges for influenza vaccines Regulatory
More informationIncidence of GBS and CIDP following influenza vaccination
Incidence of GBS and CIDP following influenza vaccination 1 National Influenza Immunization Program (NIIP) Analysis of the national surveillance data on GBS cases between October 1, 1976 and January 31,
More informationEpidemiology and Control of Pertussis in England: Impact of Maternal Immunisation Dr Gayatri Amirthalingam
Epidemiology and Control of Pertussis in England: Impact of Maternal Immunisation Dr Gayatri Amirthalingam Immunisation, Hepatitis & Blood Safety department Public Health England 12 th November 2015 Session
More informationVaccine Safety: Its everyone s business! PHO Rounds: Nov 19, 2013
Vaccine Safety: Its everyone s business! PHO Rounds: Nov 19, 2013 Tara Harris, Nurse Consultant Shelley Deeks, Medical Director Immunization and Vaccine Preventable Diseases 1 Learning objectives 1. Describe
More informationVaccine Safety: the risk of undermining our successes at the global level
Vaccine Safety: the risk of undermining our successes at the global level Pan-American Vaccine Safety Summit May 10, 2012 1 nsafe vaccine can have serious consequences Safety crises derail immunization
More informationSentinel Initiative Public Workshop. The Brookings Institution Marriott at Metro Center Washington, DC Tuesday, January 14, 2014
Sentinel Initiative Public Workshop The Brookings Institution Marriott at Metro Center Washington, DC Tuesday, January 14, 2014 State of CBER s Mini-Sentinel Activities Michael Nguyen, MD Division of Epidemiology
More informationMMR vaccine and idiopathic thrombocytopaenic purpura
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Publishing 200355Short ReportMMR vaccine and idiopathic thrombocytopaenic purpurac. Black et al. MMR vaccine
More informationWHO INFLUENZA VACCINE RECOMMENDATION
WHO INFLUENZA VACCINE RECOMMENDATION Strategic Advisory Group of Experts (SAGE) on Immunization SAGE Working Group on Influenza Vaccine and Immunization 1 Evidence Evaluation: Conceptual Matrix Target
More informationVaccinology 2017 Hanoi, Vietnam October 2017
Vaccinology 2017 Hanoi, Vietnam October 2017 Active surveillance to assess vaccine benefits and risks Associate Professor Kristine Macartney National Centre for Immunisation Research and Surveillance University
More informationOverview of the PAHO strategy and activities to strengthen National Regulatory Authorities in the Americas
Overview of the PAHO strategy and activities to strengthen National Regulatory Authorities in the Americas Ma. de los Angeles Cortes Regional Advisor on Vaccines and Biologicals HSS/MT Annecy, France March
More informationConfounding in influenza VE studies in seniors, and possible solutions
Confounding in influenza VE studies in seniors, and possible solutions Michael L. Jackson Group Health Research Institute 4 th December, 2012 1 Outline Focus is on non-specific outcomes (e.g. community-acquired
More informationSWINE FLU IT STOPS WITH YOU. Getting the Swine Flu vaccine will protect you from Swine Flu and will also stop it spreading to people around you.
SWINE FLU IT STOPS WITH YOU Getting the Swine Flu vaccine will protect you from Swine Flu and will also stop it spreading to people around you. The HSE is working to offer a Swine Flu Vaccine to everyone
More informationPneumococcal vaccination in UK: an update. Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections
Pneumococcal vaccination in UK: an update Dr Richard Pebody Immunisation Department Health Protection Agency Centre for Infections Leading infectious causes of mortality, 2000 WHO estimates 3.5 Deaths
More informationVaccine Safety Datalink (VSD)
Vaccine Safety Datalink (VSD) Overview Immunization Safety Branch National Immunization Program Institute of Medicine (IOM) Reports on Vaccine Safety "Many gaps and limitations" in current knowledge +
More informationMaternal influenza immunisation
Maternal influenza immunisation Cheryl Cohen Centre Head Centre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases cherylc@nicd.ac.za Global causes of death in children
More informationPandemic lessons learnt
Pandemic lessons learnt PCWP-HCPWG Joint meeting 28 February 2012 Presented by: Ragini Shivji, Monika Benstetter EMA An agency of the European Union Overview of presentation Background & Objective European
More informationChildhood immunisation: An Update
Childhood immunisation: An Update Helen Bedford Senior Lecturer in Children s Health UCL Institute of Child Health h.bedford@ucl.ac.uk June 11 th 2013 Immunisation Part of Healthy Child Programme HVs and
More informationSeasonal influenza vaccination programme country profile: United Kingdom Northern Ireland
Seasonal influenza vaccination programme country profile: United Kingdom Northern Ireland 2012 13 Season Background information Influenza immunisation policy and general facts about the United Kingdom
More informationResponding to Vaccine Safety Events
Responding to Vaccine Safety Events Karen Midthun, MD, Deputy Director Center for Biologics Evaluation and Research, FDA ICDRA Conference Berne, Switzerland September 19, 2008 1 Vision for CBER INNOVATIVE
More informationWhy is surveillance important after introducing vaccines?
Why is surveillance important after introducing vaccines? Dr Michael Edelstein Immunisation Department, National Infections service Public Health England @epi_michael BSAC Spring conference, 12 th March
More informationShould i get the H1N1 Vaccine?
Should i get the H1N1 Vaccine? 2 comments and 10 questions.. 12 slides Dr. Mike Evans Associate Professor, Family & Community Medicine, University of Toronto, Staff Physician, St. Michael s Hospital Director,
More informationImmunisation against infectious disease Updates Chapter 23a Pandemic influenza A(H1N1)v 2009 (swine flu)
Immunisation against infectious disease Updates Chapter 23a Pandemic influenza A(H1N1)v 2009 (swine flu) p.1 Chapter title Delete (swine flu) p.2 History and epidemiology of the disease Replace second
More informationAnswer keys for Assignment 4: Measures of disease frequency
Answer keys for Assignment 4: Measures of disease frequency (The correct answer is underlined in bold text) 1. This statistic is used to estimate the risk of acquiring a disease. It may be measured as
More informationSeasonal influenza vaccination programme country profile: United Kingdom Scotland
Seasonal influenza vaccination programme country profile: United Kingdom Scotland 2012 13 Season Background information Influenza immunisation policy and general facts about the United Kingdom Volume indices
More informationTuning Epidemiological Study Design Methods for Exploratory Data Analysis in Real World Data
Tuning Epidemiological Study Design Methods for Exploratory Data Analysis in Real World Data Andrew Bate Senior Director, Epidemiology Group Lead, Analytics 15th Annual Meeting of the International Society
More informationLessons Learned from Adverse Events and Assessment of Causal Relationships. Neal A. Halsey Johns Hopkins University
Lessons Learned from Adverse Events and Assessment of Causal Relationships Neal A. Halsey Johns Hopkins University Lessons Learned 1000s of lessons learned Many vaccines not successful Some caused harm
More informationEffectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases
TECHNICAL DOCUMENT Effectiveness of rotavirus vaccination Generic study protocol for retrospective case control studies based on computerised databases www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Effectiveness
More informationin control group 7, , , ,
Q1 Rotavirus is a major cause of severe gastroenteritis among young children. Each year, rotavirus causes >500,000 deaths worldwide among infants and very young children, with 90% of these deaths occurring
More informationTexas Immunization Coverage Levels TVFC Conference-Permian Basin April 20, 2016
Texas Immunization Coverage Levels TVFC Conference-Permian Basin April 20, 2016 www.immunizetexas.com Impact of Immunization Programs The routine childhood immunization program* of 4.3 million children
More informationVaccination schedules in Denmark
Vaccination schedules in Denmark Tyra Grove Krause MD, PhD, Senior consultant Head of Dept. Of Infectious Disease Epidemiology and Prevention Statens Serum Institut e-mail: tgv@ssi.dk Agenda History of
More informationClinical trials: Role of a DSMB
Clinical trials: Role of a DSMB 15 th Advanced Course of Vaccinology May 15, 2014 Penny M. Heaton, MD Director of Vaccine Development Vaccine Development: Catalyze development of low cost vaccines that
More informationPostmarketing surveillance of pandemic H1N1 vaccines
Postmarketing surveillance of pandemic H1N1 vaccines Dr Dina Pfeifer and Dr Claudia Alfonso Department of Immunization, Vaccines and Biologicals Quality, Safety and Standards Scene To date major public
More informationImmunization Safety Office: Overview and Considerations on Safety of Alternative Immunization Schedules
Immunization Safety Office: Overview and Considerations on Safety of Alternative Immunization Schedules Frank DeStefano MD, MPH Immunization Safety Office Division of Healthcare Quality Promotion, National
More informationHighland NHS Board 6 October 2015 Item 5.1 NEW VACCINATION PROGRAMMES
Highland NHS Board 6 October 2015 Item 5.1 NEW VACCINATION PROGRAMMES Report by Abhayadevi Tissington, Nurse Consultant Health Protection and Ken Oates, Consultant in Public Health on behalf of Hugo Van
More informationDeployment of Combination Vaccines and STI vaccines
Deployment of Combination Vaccines and STI vaccines Advancing Prevention Technologies for Sexual and Reproductive Health Symposium Berkeley, Ca March 24, 2009 Eileen Yamada, MD, MPH California Department
More informationUpdate on A(H1N1) pandemic and seasonal vaccine availability. July 7, 2009
Update on A(H1N1) pandemic and seasonal vaccine availability July 7, 2009 Presentation objectives and approach Presentation Objectives Review production status for 2009-2010 Northern Hemisphere vaccine
More informationUK Childhood Live Attenuated Influenza Vaccination Programme
UK Childhood Live Attenuated Influenza Vaccination Programme Epidemiological report of pilot programme in : contribution of RCGP network Respiratory Diseases Department CIDSC Public Health England Background
More informationUS Efforts in Vaccine Safety. Roger Baxter, MD California Immunization Coalition Summit 2011
US Efforts in Vaccine Safety Roger Baxter, MD California Immunization Coalition Summit 2011 Conflicts of interest I receive research grants from Sanofi Pasteur, GSK, Merck, MedImmune, Novartis, Pfizer,
More informationImpact and effectiveness of national immunisation programmes. David Green, Nurse Consultant, Immunisations Public Health England
Impact and effectiveness of national immunisation programmes David Green, Nurse Consultant, Immunisations Public Health England Session objectives Immunisation planning and implementation The impact and
More informationRegulatory requirements for universal flu vaccines Perspective from the EU regulators
Regulatory requirements for universal flu vaccines Perspective from the EU regulators EDUFLUVAC workshop 12-14 June Marco Cavaleri Head of Anti-infectives and Vaccines Scientific & Regulatory Management
More informationNational Narcolepsy Study Steering Committee. Download date 20/10/ :08:25.
Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010: final report of National Narcolepsy Study Steering Committee Item Type Report Authors National
More informationUpdate on H1N1 vaccine immunogenicity, safety and effectiveness
Update on H1N1 vaccine immunogenicity, safety and effectiveness Dr David J Wood QSS/IVB/WHO SAGE 14 Apr 10 Immunogenicity outcomes (SAGE Oct 2009) Both adjuvanted and non-adjuvanted inactivated influenza
More informationGlobal Vaccine Safety Initiative Activities Portfolio
Global Vaccine Safety Initiative Activities Portfolio 2012-2020 World Health Organization Switzerland April Activities Description Global Vaccine Safety initiative activities portfolio Introduction The
More information2016/17 Vaccination and Immunisation list of additional services and enhanced services
2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services Version number: 1 First published:
More informationCurrent (+ Future) Vaccine Safety Data Sources. Robert T. Chen MD, MA Vaccine Safety and Development Activity National Immunization Program
Current (+ Future) Vaccine Safety Data Sources Robert T. Chen MD, MA Vaccine Safety and Development Activity National Immunization Program Outline Current data sources Pre-licensure Post-licensure Strengths
More informationThe English immunization programme
The English immunization programme Mary Ramsay Head of Immunisation Public Health England National Health Service Constitution (2009) You have the right to receive the vaccinations that the Joint Committee
More informationPaper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2013:
Paper provided by MHRA for Joint Committee on Vaccination and Immunisation October 2013: VACCINE-ASSOCIATED SUSPECTED ADVERSE REACTIONS REPORTED VIA THE YELLOW CARD SCHEME DURING 2012/13 September 2013
More information2017/18 Immunisation programmes list of additional and enhanced services
2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2017 Prepared
More informationVaccine 30 (2012) Contents lists available at ScienceDirect. Vaccine. j ourna l ho me pag e:
Vaccine 30 (2012) 3042 3046 Contents lists available at ScienceDirect Vaccine j ourna l ho me pag e: www.elsevier.com/locate/vaccine A collaborative approach to investigating the risk of thrombocytopenic
More informationBurden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination
Carlo GIAQUINTO Pediatrics Department University of Padova, Italy Burden of Paediatric Rotavirus Gastroenteritis & Potential Impact of Rotavirus Vaccination Preliminary results 7th International Rotavirus
More information2018/19 Immunisation programmes list of additional and enhanced services
2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2018 Prepared
More informationRisk and Uncertainty. The Precautionary Principle: Immunisation safety: risks, benefits and precautions.
Risk and Uncertainty The Precautionary Principle: Immunisation safety: risks, benefits and precautions. Prof. David Salisbury CB Director of Immunisation, Department of Health. The precautionary principle
More informationWe have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci
We have a new vaccine: Now what are we going to do with it? Prof. David Salisbury CB FRCP FRCPCH FFPH FMedSci Pressures for new vaccine introduction. International institutions. Vaccine manufacturers National
More informationGlobal Vaccine Safety Initiative Portfolio activities
Global Vaccine Safety Initiative Portfolio activities 2012-2020 Safety and Vigilance (SAV) Health Systems and Innovation (HIS) World Health Organization Geneva, Switzerland October 2013 ii Table of Contents
More informationTHIS TALK STATINS REDUCE: Immortal time bias Immeasurable time bias Time-window bias TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY
TIME-RELATED BIASES IN PHARMACOEPIDEMIOLOGY Samy Suissa McGill University and Jewish General Hospital Montreal, Canada ISPE mid-year meeting, Miami April 22, 2012 STATINS REDUCE: JAMA 2000: Fracture rate
More informationQuestions and answers about HPV. Facts about the virus and the vaccine
Questions and answers about HPV Facts about the virus and the vaccine About the introduction of the human papillomavirus (HPV) vaccine Which countries have introduced the HPV vaccine? Over 100 countries
More informationIncorporating Clinical Information into the Label
ECC Population Health Group LLC expertise-driven consulting in global maternal-child health & pharmacoepidemiology Incorporating Clinical Information into the Label Labels without Categories: A Workshop
More informationCLINICAL COMMISSIONING GROUP PRIMARY CARE COMMITTEE EXECUTIVE SUMMARY
Primary Care Committee Agenda Item 7.1 CLINICAL COMMISSIONING GROUP PRIMARY CARE COMMITTEE EXECUTIVE SUMMARY SHEET DATE: 4 th July 2017 TITLE OF PAPER: Influenza Vaccination 2016-17 EXECUTIVE Chris Morris
More informationPerspectives on Improving International Vaccine Safety
Perspectives on Improving International Vaccine Safety Robert Ball, MD, MPH, ScM Director, Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research U.S. Food and Drug Administration
More informationSurveillance report Published: 9 January 2017 nice.org.uk
Surveillance report 2017 Caesarean section (2011) NICE guideline CG132 Surveillance report Published: 9 January 2017 nice.org.uk NICE 2017. All rights reserved. Contents Surveillance decision... 3 Reason
More information4/7/2017. Audrey Ofir, MD, MBA, FAAP University of Miami Miller School of Medicine Holtz Children Hospital
Audrey Ofir, MD, MBA, FAAP University of Miami Miller School of Medicine Holtz Children Hospital 1 9vHPV Tdap MCV LAIV HepB Children with Medical conditions 2 9vHPV vaccine HPV infection: Causes cervical,
More information2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary
European Medicines Agency London, 17 March 2009 Doc. Ref. EMEA/43556/2009 2008 Status Report on the Implementation of the European Risk Management Strategy Executive Summary The European Risk Management
More informationBenefits of the pneumococcal immunisation programme in children in the United Kingdom
Benefits of the pneumococcal immunisation programme in children in the United Kingdom 2006-2014 Professor Mary P E Slack mpeslack@gmail.com March 2015 Disclosure of interest The presenter has received
More informationGlobal Challenges of Pandemic and Avian Influenza. 19 December 2006 Keiji Fukuda Global influenza Programme
Global Challenges of Pandemic and Avian Influenza 19 December 2006 Keiji Fukuda Global influenza Programme Summary of Current H5N1 Situation 1997 First known outbreak infecting humans 18 people hospitalized
More informationStudy Summary (version 1.0) Risk of Febrile Convulsions after MMRV Vaccination in Comparison to MMR or MMR+V Vaccination
BIPS - Institute for Epidemiology and Prevention Research Study Summary (version 1.0) Risk of Febrile Convulsions after MMRV Vaccination in Comparison to MMR or MMR+V Vaccination Main Study: Assessment
More informationSwine Flu. Media Briefing. 13 January 2011
Swine Flu Media Briefing 13 January 2011 Overview Systems for monitoring swine flu Pattern of flu in Northern Ireland Updated swine flu deaths Vaccination programme Systems for Monitoring Flu Special arrangements
More informationChildhood flu vaccination: experiences of a new programme in England
Childhood flu vaccination: experiences of a new programme in England Richard Pebody PHE Respiratory Diseases Department, London 28 èmes Rencontres sur la grippe et sa prévention, Lyons, November 2015 UK
More information11 questions to help you make sense of a case control study
Critical Appraisal Skills Programme (CASP) making sense of evidence 11 questions to help you make sense of a case control study How to use this appraisal tool Three broad issues need to be considered when
More informationWhat s the latest on the staff vaccination programme for swine flu?
H1N1 VACCINATION PROGRAMME Healthcare professional Q&A What s the latest on the staff vaccination programme for swine flu? Scientists have now developed an approved vaccine for the A(H1N1) or Swine Flu
More informationNational Vaccine Plan: From Strategy to Implementation
National Vaccine Plan: From Strategy to Implementation July 26, 2011 Sarah Landry Senior Advisor, National Vaccine Program Office Office of the Assistant Secretary for Health Department of Health and Human
More informationEpidemiology of Influenza in the United Kingdom A/H1N1, or swine flu, in Mexico has heightened awareness of the multifaceted and
Epidemiology of Influenza in the United Kingdom 1996-2007 Introduction The recent international concern related to an important outbreak of influenza A/H1N1, or swine flu, in Mexico has heightened awareness
More informationPandemic Influenza Preparedness Subpanel
Defense Health Board Pandemic Influenza Preparedness Subpanel Gregory A. Poland, MD Vice-President, Defense Health Board Chair, Select Subcommittee on PI Planning and Response Purpose Brief Background
More informationNational Immunisation Programme changes Michael Baker. Wessex Public Health England Centre
National Immunisation Programme changes 2013-14 Michael Baker Wessex Public Health England Centre Changes to the Meningococcal serogroup C conjugate (MenC) vaccine schedule in 2013 2 Immunisation Programme
More informationBristol and South Gloucestershire School Aged Immunisation Pathways for the 2018/19 academic year
Bristol and South Gloucestershire School Aged Immunisation Pathways for the 2018/19 academic Introduction This information is aimed to support local practices in understanding school aged immunisations,
More informationThe story of modern vaccines begins in 1749, when Dr. Edward Jenner observed that milkmaids exposed to cowpox later subsequently not contract
1 The story of modern vaccines begins in 1749, when Dr. Edward Jenner observed that milkmaids exposed to cowpox later subsequently not contract smallpox. Dr. Jenner used fluids from a cow s blisters to
More informationThe schedule for childhood vaccination is:(web link to NHS Childhood Immunisation Schedule for 2008
Immunisations and vaccinations Immunisation is an effective public health intervention for promoting good health and protecting individuals and populations against serious disease and infection through
More informationGSK VACCINES: KEY GROWTH DRIVERS
GSK VACCINES: KEY GROWTH DRIVERS Martin Andrews Senior Vice President, Global Vaccines Centre of Excellence, GSK Biologicals Millions of children die from infectious diseases Many of these deaths are preventable
More informationNational seasonal influenza vaccination programmes in Europe
National seasonal influenza vaccination programmes in Europe Pasi Penttinen, head of disease programme (acting) Office of the Chief Scientist European Centre for Disease Prevention and Control (ECDC) Brussels,
More information3. Title Vaccination and immunisation data return collected through the COVER
1. Record Type? 2. Unique Number Reassessment R00019 3. Title Vaccination and immunisation data return collected through the COVER 4. Collection Type National 5. Other Reference 6. Description Cover of
More informationDisparities in influenza vaccination coverage rates in health care workers and the ways to overcome the barriers
Disparities in influenza vaccination coverage rates in health care workers and the ways to overcome the barriers Dr. Patricia R. Blank Barcelona - November 15, 2012 The Menu 1. Situation in Europe Recommendations
More informationRole of vaccination and the evaluation of LSD control programmes
Role of vaccination and the evaluation of LSD control programmes Dr Nick Lyons FAO Workshop: LSD prevention and control Tbilisi, Georgia, 11th November 2015 Vaccines and protection Susceptible Infected
More informationData and Approaches in National and International Immunization Studies. Emory University, Schools of Public Health & Medicine & CHRSE
Data and Approaches in National and International Immunization Studies Saad B. Omer, MBBS MPH PhD Emory University, Schools of Public Health & Medicine & CHRSE Outline Characteristics of vaccine refusers
More informationVaccinating Against the Pandemic H1N1 Influenza Virus. Background. Milestones in Influenza Vaccine Development. Increased Safety, Less Reactogenicity
Vaccinating Against the Pandemic H1N1 Influenza Virus Background Alvin Nelson El Amin, MD, MPH Medical Director Immunization Program Milestones in Influenza Vaccine Development Isolation of the influenza
More informationWHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES
WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES SURVEY QUESTIONNAIRE A.1. Introduction The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 as a ten year initiative to address the anticipated
More informationMonitoring vaccine safety using case series CUSUM charts
Monitoring vaccine safety using case series CUSUM charts Patrick Musonda 1, Mounia N. Hocine 1, Nick J. Andrews, C. Paddy Farrington 1 1 Department of Mathematics and Statistics, The Open University, Milton
More informationGSK Medicine: Study No.: Title: Rationale: Study Period Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More information